IDH2 and acute myeloid leukemia: These therapies range from targeted single agents (enasidenib, which targets mutant IDH2 [mIDH2] AML) and multi-kinase inhibitors (midostaurin) to a fixed drug combination for induction chemotherapy (CPX-351) and the re-approval of an antibody–drug conjugate that targets CD33 (GO).